Clearmind testifies at FDA hearing on psychedelic therapies

VANCOUVER, Canada - On September 14, Clearmind Medicine Inc. (NASDAQ:CMND) appeared before a federal panel convened by the FDA to consider the future therapeutic use of psychedelic drugs. Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind, presented findings from the company's clinical trials at Yale and Johns Hopkins universities.

Gifford highlighted the potential of neuroplastogenic compounds to maintain therapeutic benefits while removing hallucinogenic effects, suggesting these substances could lower costs associated with supervised dosing. The FDA hearing invited input on various aspects, including patient access, provider training, patient safety, and data collection.

Tiffany R. Farchione, Director of the Division of Psychiatry at the FDA's Center for Drug Evaluation and Research, participated in the discussion alongside officials from SAMHSA, NIDA, ARPAH, and the Veterans Health Administration. Clearmind is a clinical-stage biopharmaceutical company focusing on neuropsychiatric, metabolic, and addiction disorders.

Their drug candidate MEAI, aimed at treating alcohol use disorder, is currently in a Phase 2a trial at Yale and Johns Hopkins. Clearmind holds 19 patent families, with 32 patents already granted.